Advertisement

Astra rebuffs 'final' Pfizer bid

US drugs giant Pfizer's attempt to takeover AstraZeneca has come to a dead-end.

US pharmaceutical group Pfizer appears to have lost the battle for Anglo-Swedish rival AstraZeneca. The firm's final offer of £55 per share was rejected by Astra's board as inadequate.

Unless shareholders put pressure on the board to reconsider before the deadline of 26 May, Pfizer will have to wait three months to make a higher offer with Astra's approval, or six months if it wants to mount a hostile bid.

What the commentators said

A bid of £60 might well have tipped the balance, but by tabling a "take-it-or-leave-it" bid and urging Astra's shareholders to revolt, the firm badly miscalculated.

Advertisement - Article continues below

"Pfizer has a risky way back into a deal," said Chris Hughes on Breakingviews.com. It has the right to raise its final price if the offer is accepted, so it could signal to Astra's board that if Astra were to accept £55, Pfizer would immediately significantly increase it.

But the Takeover Panel, which oversees deals in the UK, would not be keen on an attempt to bend the rules and might well block the bid.

So could Pfizer return in six months? Probably not, said Kamal Ahmed on BBC.co.uk. By then, "AstraZeneca shareholders believe the US government will have gone a long way to closing the tax loophole which was one of the reasons for Pfizer being so attracted to AstraZeneca." The bid seems to be dead.

Advertisement
Advertisement

Recommended

Visit/517688/the-british-equity-market-is-shrinking
Stockmarkets

The British equity market is shrinking

British startups are abandoning public stockmarkets and turning to deep-pocketed Silicon Valley venture capitalists for their investment needs.
8 Nov 2019
Visit/511212/reasons-for-investors-to-be-bearish-but-stick-with-the-stockmarket-bulls
Stockmarkets

There are lots of reasons to be bearish – but you should stick with the bulls

There are plenty of reasons to be gloomy about the stockmarkets. But the trend remains up, says Dominic Frisby. And you don’t want to bet against the …
17 Jul 2019
Visit/510684/good-news-on-jobs-scares-stockmarkets
Economy

Good news on jobs scares US stockmarkets

June brought the best monthly US jobs growth of the year, but stockmarkets were not best pleased.
11 Jul 2019
Visit/510135/trade-war-ceasefire-boosts-stockmarkets
Economy

Trade-war ceasefire boosts stockmarkets

Stockmarkets sighed with relief after the G20 summit in Japan brought a handshake between Donald Trump and Xi Jinping.
4 Jul 2019

Most Popular

Visit/investments/commodities/industrial-metals/601401/money-printing-infrastructure-base-metals-copper
Industrial metals

Governments’ money-printing mania bodes well for base metals

Money is being printed like there is no tomorrow. Much of it will be used to pay for infrastructure projects – and that will be good for metals, says …
27 May 2020
Visit/investments/investment-strategy/601389/are-you-a-permabear-three-red-flags-to-watch-out-for
Investment strategy

Are you a permabear? Three red flags to watch out for

Contrarian investors are often seen as bearish because the market tends to go up over time. But if that bearishness goes too deep, you risk seriously …
26 May 2020
Visit/economy/eu-economy/601422/heres-why-investors-should-care-about-the-eus-plan-to-tackle-covid-19
EU Economy

Here’s why investors should care about the EU’s plan to tackle Covid-19

The EU's €750bn rescue package makes a break-up of the eurozone much less likely. John Stepek explains why the scheme is such a big deal, and what it …
28 May 2020